ALZpath
San Diego, United States· Est.
ALZpath provides a proprietary pTau217 antibody that powers early, blood‑based Alzheimer’s disease detection for diagnostics partners.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
ALZpath provides a proprietary pTau217 antibody that powers early, blood‑based Alzheimer’s disease detection for diagnostics partners.
Alzheimer's disease
Technology Platform
Proprietary monoclonal antibody (pTau217) enabling ultra‑sensitive, blood‑based detection of phosphorylated tau for early Alzheimer’s diagnosis.
Opportunities
Expanding licensing agreements with global diagnostics manufacturers and developing multiplexed biomarker panels to broaden clinical utility and market penetration.
Risk Factors
Dependence on partner adoption, regulatory clearance for in‑vitro diagnostic use, and competition from other blood‑based Alzheimer’s biomarkers.
Competitive Landscape
Competes with companies such as C2N, Eli Lilly, and ADx Neurosciences; differentiation lies in the proprietary pTau217 antibody’s demonstrated equivalence to PET/CSF and its integration across multiple assay platforms.